|
TAF1A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.64757096854373E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.38298311375729E-14 |
| Normal-vs-Stage2 |
1.6269208202857E-12 |
| Normal-vs-Stage3 |
1.80899739632423E-12 |
| Normal-vs-Stage4 |
1.00364161426114E-13 |
| Stage1-vs-Stage2 |
3.667800E-02 |
| Stage1-vs-Stage3 |
9.402000E-01 |
| Stage1-vs-Stage4 |
4.471400E-01 |
| Stage2-vs-Stage3 |
6.216400E-02 |
| Stage2-vs-Stage4 |
2.329000E-01 |
| Stage3-vs-Stage4 |
5.159800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.89208714941014E-14 |
| Normal-vs-AfricanAmerican |
2.45409999988233E-07 |
| Normal-vs-Asian |
1.13908882326541E-13 |
| Caucasian-vs-AfricanAmerican |
6.037200E-01 |
| Caucasian-vs-Asian |
2.591800E-01 |
| AfricanAmerican-vs-Asian |
2.037600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.66133814775094E-16 |
| Normal-vs-Female |
1.01474384450739E-13 |
| Male-vs-Female |
2.704300E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.48290318597356E-14 |
| Normal-vs-Age(41-60Yrs) |
1.66289204628356E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
4.92840000032579E-07 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.117200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.316000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.676200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.711800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.358400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.573200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.504010E-01 |
| Classical-VS-Follicular |
8.624400E-04 |
| Classical-VS-Other |
9.005900E-02 |
| Classical-VS-Normal |
2.7325919305099E-12 |
| Tall-VS-Follicular |
2.662400E-01 |
| Tall-VS-Other |
1.912410E-01 |
| Tall-VS-Normal |
1.70907732410797E-12 |
| Follicular-VS-Other |
6.438000E-01 |
| Follicular-VS-Normal |
1.62436730732907E-12 |
| Other-VS-Normal |
2.26669999999762E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.88578058618805E-15 |
| Normal-vs-N1 |
5.71098723867181E-12 |
| N0-vs-N1 |
6.160600E-01 |
|
|
